AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Taro Announces Resignation of Chief Financial Officer

July 14, 2021 GMT

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jul 14, 2021--

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021. Ms. Huang is leaving the Company in order to pursue other opportunities.

Mr. Uday Baldota, Taro’s CEO, stated, “On behalf of the Company, I want to thank Daphne for her valuable contributions including her efforts over the past year during the COVID-19 pandemic. We wish her the best in her future endeavors.”

The Company has initiated a search for a successor as Chief Financial Officer.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20210714005916/en/

CONTACT: William J. Coote

AVP, Treasurer

(914) 345-9001

William.Coote@taro.com

KEYWORD: UNITED STATES NORTH AMERICA ISRAEL MIDDLE EAST NEW YORK

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH

SOURCE: Taro Pharmaceutical Industries Ltd.

Copyright Business Wire 2021.

PUB: 07/14/2021 05:54 PM/DISC: 07/14/2021 05:54 PM

http://www.businesswire.com/news/home/20210714005916/en